Abstract: Paclitaxel has low solubility and permeability, so its early formulations required solvents such as polyoxyethylene castor oil. However, these excipients are prone to causing severe hypersensitivity reactions, necessitating pretreatment with antihistamines and glucocorticoids, thereby inconvenient for clinical utility. To address these challenges, modified formulations have been developed,including injections based on albumin, liposomes, and micelles as delivery carriers, as well as oral preparations. These novel formulations offer advantages such as significant efficacy, reduced adverse effects, and convenient administration. This review summarizes the clinical progress of modified paclitaxel formulations, aiming to provide references for the formulation design of paclitaxel and its rational clinical use.